Applies to Medicaid plans.
Not coveredEffective January 1, 2026, drugs containing a GLP-1 receptor agonist are not covered for the treatment of overweight or obesity for MA beneficiaries. The policy states: 'GLP-1 Receptor Agonists are not covered for the treatment of overweight or obesity.'
Policy note: Pennsylvania MA explicitly ended coverage of all GLP-1 receptor agonists for overweight/obesity effective January 1, 2026. Class-wide exclusion applies to Zepbound for weight loss indication.
Policy effective January 1, 2026 · verified June 4, 2026 · source: Mab2025112403 · View policy document (PDF)